COVID-19

The COVID vaccine market is worth at least $150 billion. Can we stop it being flooded with fakes?

Empty vials of Pfizer/BioNTech's Comirnaty vaccine.

Empty vials of Pfizer/BioNTech's Comirnaty vaccine. Image: Reuters

Share:
Our Impact
What's the World Economic Forum doing to accelerate action on COVID-19?
The Big Picture
Explore and monitor how COVID-19 is affecting economies, industries and global issues
A hand holding a looking glass by a lake
Crowdsource Innovation
Get involved with our crowdsourced digital platform to deliver impact at scale
Stay up to date:

COVID-19

  • Countries all over the world are reporting the sale of fake, or misleadingly labelled, vaccines.
  • Counterfeit COVID vaccines are part of the rapidly increasing worldwide trade in fake medicines that poses a grave threat to health.
  • Blockchain-backed traceability systems could be used to authenticate drugs – paired with secure labels.

In the past, forgers have targeted currency, artworks, even wine. Now, COVID-19 vaccines are in their sights. In July, CNN reported thousands of people had fallen prey to a scam selling fake coronavirus vaccines in India, with doctors and medical workers among those arrested for their involvement. At least 12 fake vaccination drives were held in or near the financial hub of Mumbai. Around 2,500 people who thought they were being administered a legitimate AstraZeneca dose were in effect receiving saline – and paid for the privilege. Another fake vaccination camp had been exposed a few days earlier in June by the Times of India, this time involving the Russian Gamaleya vaccine.

The World Health Organization’s Director-General, Dr. Tedros Adhanom Ghebreyesus, had already issued a warning in March about counterfeit COVID vaccines being sold on the dark web. This turn of events serves to remind the world about the dramatic impact of drug counterfeiting, a booming organized crime industry growing at the staggering pace of 20% annually. Back in 2017, PwC (conservatively) estimated the market to be worth $200 billion. When more than 10% of drugs sold worldwide are allegedly fake, in some low-income countries more than 50% of drugs administered to patients are counterfeit, causing more than 1 million deaths annually according to Interpol – higher than ones caused by suicide or illicit drug abuse.

Other countries are also seeing similar pandemic-exploiting crime. In April, Pfizer reported identifying counterfeit versions of its coronavirus vaccine in Mexico and Poland. The Mexican health regulatory agency, COFEPRIS, has issued six health alerts since January 2021, against the illegal sale of a long list of counterfeit AstraZeneca, Cansino, Moderna, Sinovac, Sinopharm and Pfizer COVID-19 vaccines. (Sinopharm and Moderna shots aren’t even officially available there).

Have you read?

No country is immune; even ones with broad vaccine availability like the USA and Israel, where some unscrupulous doctors and pharmacists have been caught selling empty vaccine vials on Craigslist or eBay. Do we seriously believe those vials are intended for a museum, especially when some buyers acquire dozens at a time? Search yourself, like I did, and you will easily find them.

Empty COVID vaccine vials for sale on eBay
Empty COVID vaccine vials for sale on eBay

This was all sadly predictable. When a market with the potential to reach $150 billion in pharma revenues for the 2021-2022 period emerges in record time, this will loom large on the criminal radar. It threatens us with the depressing prospect of a scenario where in some countries, despite the remarkable efforts of GAVI, CEPI and UNICEF in support of the equitable vaccine initiative COVAX, the illicit trade of COVID-19 vaccines results in counterfeiting levels comparable to other medicines. It would be nearly impossible for the world to reach herd immunity if 10%, 20% or more of vaccines were fake.

UNICEF well understands what a catastrophe this would be; why they are currently running a tender for the development of a blockchain-based solution, the Global Trust Repository (the GTR). To quote the tender document: “Falsification and illegal diversion of legitimate COVID vaccines pose a real and present threat. Fake vaccines impact public health, the economy, and could undermine confidence and impact COVID vaccine demand and hesitancy.”

Counterfeit medicines are a worldwide problem
Counterfeit medicines are a worldwide problem Image: Stibo Systems

The creation of the GTR is certainly good news as the vast majority of the 92 low- and middle-income countries served by COVAX have no national traceability systems in place to allow the tracking or verification of COVID-19 vaccines. In the absence of such systems, a verification solution is being proposed to all 92. It will allow COVID-19 packs in the legitimate supply chain to be scanned and verified, meaning their unique serialized product code number will be compared with a blockchain-secured repository of product codes originally generated by the manufacturers (the GTR).

This should ensure that many fake products will be identified and removed from the supply chain. Unfortunately, we are talking only a portion of them, as criminals’ appetite for big profit will not be fully deterred by this first step. Remember that according to Global Financial Integrity, medicines counterfeiting is the single most lucrative market of all transnational crimes; between 10 and 25 times more profitable than narcotics trafficking, according to the International Institute for Anti-Counterfeit Drug Research.

Discover

What is the World Economic Forum doing to manage emerging risks from COVID-19?

To counteract tampering with labels, drug manufacturers may eventually embed security features like invisible labels in primary packaging. This second step effort is no different in principle from watermarking with which banks secure their bank notes, or how governments mark cigarette packets to fully capture excise taxes. Reinforcing the connection between the physical product and its digital twin is what will finally defeat vaccines counterfeiting criminals. Promoting the second step is where the pharma industry can step up to better support UNICEF’s timely initiative.

Don't miss any update on this topic

Create a free account and access your personalized content collection with our latest publications and analyses.

Sign up for free

License and Republishing

World Economic Forum articles may be republished in accordance with the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Public License, and in accordance with our Terms of Use.

The views expressed in this article are those of the author alone and not the World Economic Forum.

Related topics:
COVID-19Global HealthHealth and Healthcare
Share:
World Economic Forum logo
Global Agenda

The Agenda Weekly

A weekly update of the most important issues driving the global agenda

Subscribe today

You can unsubscribe at any time using the link in our emails. For more details, review our privacy policy.

Winding down COVAX – lessons learnt from delivering 2 billion COVID-19 vaccinations to lower-income countries

Charlotte Edmond

January 8, 2024

About Us

Events

Media

Partners & Members

  • Join Us

Language Editions

Privacy Policy & Terms of Service

© 2024 World Economic Forum